Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery Platform
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Flagship And Pfizer To Discover Novel Autoimmune Inhibitors
Details : The collaboration aims to discover compounds which may lead to the development of next-generation therapeutics for autoimmune diseases.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 01, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery Platform
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Discovery
Sponsor : GSK
Deal Size : $7,200.0 million
Deal Type : Collaboration
GSK becomes Flagship's latest partner in $7B biobucks respiratory, immunology pact
Details : The Flagship collaborates with GSK to discover and develop a portfolio of future transformational medicines and vaccines for the treatment of respiratory and immunology diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $150.0 million
July 29, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Discovery
Sponsor : GSK
Deal Size : $7,200.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Novo Nordisk will provide funding for initiated research programmes and have an exclusive option to license each program. The ambition is to initiate three to five research programs within the first three years of the collaboration.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 05, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Discovery
Sponsor : Cystic Fibrosis Foundation
Deal Size : $110.0 million
Deal Type : Partnership
Details : Pioneering Medicines and the Cystic Fibrosis Foundation will partner with multiple companies within the Flagship ecosystem, leveraging emerging technologies including Tessera Therapeutics’ Gene WritingTM technology, targeted delivery modalities, and RN...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 11, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery
Sponsor : Cystic Fibrosis Foundation
Deal Size : $110.0 million
Deal Type : Partnership